12th October 2025
Contura Orthopaedics Supports World Arthritis Day - latest efficacy & safety data presented at ICRS to mark the global campaign
Every year on October 12th, we stand with others in the joint health community to mark World Arthritis Day, a global campaign to shine a light on the realities of living with arthritis. We believe that access to safe and effective treatment options is vital to move forward in the fight against knee OA. This year, World Arthritis Day falls during the 18th ICRS World Congress: Joint Revolution in Boston, USA (11-14 October 2025). This annual meeting of the International Cartilage Regeneration & Joint Preservation Society sees global leaders and innovators across the sector come together to share the latest clinical research, discuss innovations in treatment, and debate innovative approaches.
The Contura Orthopaedics team is delighted to have a presence as this prestigious conference once again, to ensure that Arthrosamid® continues to be part of the conversation around improving treatment options for patients. As part of this drive, two of our most recent clinical studies - 10-year safety data and 5-year efficacy study (ROSA-5) - will be presented at the prestigious ICRS World Congress.
Key Arthrosamid® Studies Presented at ICRS 2025
| Date | Study | Authors | Summary |
| Sunday 12th October (16.15-16.25) | Polyacrylamide Hydrogel for Knee Osteoarthritis: 5-Year Results from a Prospective Study (ROSA).1 | H. Bliddal, J. Beier, A. Hartkopp, P. Conaghan, M. Henriksen; Copenhagen/DK, Odense/DK, Holte/DK, Leeds/GB | A single 6mL intra-articular injection of 2.5% iPAAG provides sustained, clinically meaningful symptom relief and is well tolerated over a 5-year period in patients with moderate-to-severe knee OA. |
11-14th October (On-demand) | Abstract 339. 10-year Follow-up After Intra-Articular Injections Of 2.5 % Polyacrylamide Hydrogel for Knee Osteoarthritis2 | H.Bliddal, A. Hartkopp, P. Conaghan, M. Henriksen; Copenhagen/DK, Holte/DK, Leeds/GB) | Long-term results after 2.5% iPAAG indicated a favourable safety profile of the product, with very few patients recalling pain or problems post-injection. Surgical records from subsequent knee replacements gave no indications of unusual adverse reactions. |
Learn more
Both 10-year safety data and 5-year efficacy study ROSA-5 will be available during the official poster sessions—do not miss the chance to explore the long-term impact and clinical relevance of these findings by visiting the ICRS World Congress website.
The Impact of Knee Osteoarthritis in the UK
A staggering 10 million people of all ages in the UK live with arthritis3 – meaning one in six people living with the pain, fatigue, immobility, and reduced dexterity it can cause. Of this group, an estimated 5.4 million people have knee osteoarthritis (OA).
As many of those in our growing patient community know all too well, conditions such as knee osteoarthritis can have a significant impact physically, mentally and emotionally, Studies suggest that pain is the most common symptom experienced by patients with knee osteoarthritis.4 The ripple effect of pain, discomfort and immobility is far reaching.
Supporting Patients with Knee Osteoarthritis
Contura Orthopaedics recognises that every patient’s journey with knee osteoarthritis is unique. Knee OA can affect people’s ability to work, enjoy leisure activities and sport, carry out everyday tasks such as walking the dog or shopping, and can impact relationships with friends, family, and partners. Additionally, caregivers may find it challenging to support someone with knee osteoarthritis and often seek helpful approaches.
That’s why we are committed to supporting people at every stage, from diagnosis to treatment and beyond. Arthrosamid® has already helped more than 20,000 patients and is now available in over 400 clinics across Europe, Canada, and New Zealand. 5 By making innovative, non-surgical treatment options more accessible, we aim to empower patients and their support networks to regain mobility, independence, and quality of life.
Read Stories from our Patient Community here.
References:
1.Bliddal, H., et al. (2025). 5-Year Follow-up. Presented at EKS 2025 Copenhagen.
2.Bliddal, H., et al. (2025). 5-Year Follow-up. Presented at EKS 2025 Copenhagen.
3. The State of Musculoskeletal Health, Versus Arthritis
4. Torres, L., et al. (2006). Osteoarthritis and Cartilage. Vol 14(10):1033-40.
5. Data on file.